Navigation Links
InVitria Optimizes Hybridoma Cell Culture with New Product Zap-Hybridoma
Date:3/3/2010

For diagnostic and monoclonal antibody production, Zap-Hybridoma improves target antibody purity and hybridoma productivity.

Fort Collins, CO (PRWEB) March 3, 2010 -- InVitria’s launch of Zap-Hybridoma provides a powerful solution for hybridoma cell culture. Zap-Hybridoma was created to improve monoclonal antibody productivity and deliver easier purification of the target product.

Zap-Hybridoma was developed by InVitria’s Cell Culture Development team as an answer to many of the challenges facing scientists working with hybridoma cell culture. “Not only can Zap-Hybridoma increase productivity, it delivers consistent results and allows hybridoma cells to more quickly adapt away from FBS (fetal bovine serum),” said Dr. Steve Pettit, InVitria’s Director of Cell Culture Development. “We tested Zap-Hybridoma in six of the leading commercial hybridoma media on the market today and observed faster cell growth, a 50% average increase in maximum cell density and increased monoclonal antibody yield when compared to the recommended use of the manufacturer.”

“Zap-Hybridoma is an innovation InVitria is proud to bring to its customers so they can achieve better performance more consistently,” said Scott Deeter, InVitria President and CEO. "We developed Zap-Hybridoma to give users an IgG free alternative to FBS without sacrificing performance.”
                                                                                                                                                                                
Zap-Hybridoma / FBS
IgG Free                                                                                YES / NO
Consistent Performance                                                    YES / NO
Defined & Animal Component-Free                                YES / NO
Accelerates Adaptation to Serum-Free Media                YES / NO
Lowers Operating & Capital Costs                                   YES / NO
   
To order your sample of Zap-Hybridoma or to receive more information, please visit Zap-Hybridoma.

About InVitria – InVitria.com
InVitria specializes in cell culture media optimization for the biotechnology industry. InVitria develops, manufactures and markets a portfolio of high performance and well defined cell culture media components and reagents used in bioprocessing, biopharmaceutical formulation, stem cell & regenerative medicine, life science research, medical devices and diagnostics.

For more information about InVitria’s product solutions, e-mail info(at)InVitria(dot)com or call 1-800-916-8311.

###

Read the full story at http://www.prweb.com/releases/ZapHybridoma/InVitria/prweb3678694.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. InVitria Sponsors 2010 Biomanufacturing Summit
2. Online Video of InVitria's Zap-CHO Helps Scientists Maximize CHO Cell Culture Performance
3. InVitrias Better Ingredients for Better Media to be Showcased at BPI 09
4. InVitria Reveals Technology to Optimize Hybridoma Production Performance
5. InVitria Among Leading Innovators in Cell Culture Media According to Top Biotechnology Publication
6. InVitria's Cell Culture Media Components Showcased at WilBio's 2008 Cell Engineering Meeting
7. InVitrias Cellastim Delivers Superior Results in Mammalian Cell Culture
8. InVitria Touts Product Advantages at Cambridges Cell Culture Conference
9. InVitria Sponsors Cambridge Healthtechs Optimizing Cell Culture Development Conference
10. InVitria Further Strengthens Sales Team with Promotion of Brandy Sargent to Account Manager - Western United States
11. InVitria Expands Sales Team
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
InVitria Optimizes Hybridoma Cell Culture with New Product Zap-Hybridoma  
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf ... join the faculty of the University of North Carolina Kenan-Flagler Business School ... and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, ...
(Date:6/24/2016)... , June 24, 2016  Regular discussions on a ... take place between the two entities said Poloz. ... Ottawa , he pointed to the country,s ... the federal government. ... said, "Both institutions have common economic goals, why not sit ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Researchers at the ... commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject ... it now. , Diagnostic biomarkers are signposts in the blood, lung fluid or ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
Breaking Biology News(10 mins):